Plain-English translation of NCT07317609 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a type of immunotherapy drug, combined with two chemotherapy drugs ( and ) can shrink esophageal cancer enough to allow doctors to remove it using a minimally invasive endoscopic procedure instead of major surgery. Patients receive at least two cycles of the medication over several weeks, then have imaging tests to see if the tumor has shrunk significantly. If it has, they may be eligible for the less invasive removal procedure.
Currently, esophageal cancer is often treated with major surgery that removes part or all of the esophagus, which can affect a patient's quality of life. This trial explores whether giving this medication first to shrink the tumor might allow doctors to preserve the esophagus by using a minimally invasive endoscopic approach instead.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication combination once every 3 weeks for at least 2 cycles (about 6 weeks total). During treatment, you'll have regular safety blood tests and check-ins. After finishing the medication, you'll have a break of 3-4 weeks, then undergo detailed imaging tests (endoscopy, ultrasound, and CT or PET scans) to see how well the tumor has responded. If the tumor has shrunk significantly and meets certain criteria, you would then have the minimally invasive endoscopic removal procedure performed 3-6 weeks later.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China